Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI-1808 |
Synonyms | |
Therapy Description |
BI-1808 is an antibody that targets TNFR2, potentially leading to modulation of the antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 4156). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI-1808 | BI 1808|BI1808 | BI-1808 is an antibody that targets TNFR2, potentially leading to modulation of the antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 4156). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04752826 | Phase Ib/II | BI-1808 + Pembrolizumab BI-1808 | BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) | Recruiting | USA | SWE | HUN | GBR | DNK | 1 |